Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Da-h-c Cpd
2. Diammonium Hydrogen Citrate
1. 3012-65-5
2. Microstop
3. Diammonium Hydrogen Citrate
4. Dibasic Ammonium Citrate
5. Ammonium Monohydrogen Citrate
6. Ammonium Citrate, Dibasic
7. Citric Acid Diammonium Salt
8. Ammonium Citrate Dibasic
9. Ammonium Hydrogen Citrate
10. Ammonium Monohydrogencitrate
11. Citrate (diammonium)
12. 2-hydroxy-1,2,3-propanetricarboxylic Acid, Diammonium Salt
13. Mfcd00013068
14. 1,2,3-propanetricarboxylic Acid, 2-hydroxy-, Diammonium Salt
15. Ammcitrate
16. Diammonium 3-carboxy-3-hydroxypentanedioate
17. Diammonium Hydrogen 2-hydroxypropane-1,2,3-tricarboxylate
18. Citric Acid Ammonium Salt
19. Ammonium Monohydrogen Citrate; Citrate Diammonium Hydrogen
20. Ammonium Monohydrogencitrat
21. N9bug430k8
22. Chebi:63076
23. Citric Acid, Diammonium Salt
24. Diammonium Citrate (secondary)
25. Hsdb 300
26. Einecs 221-146-3
27. Unii-n9bug430k8
28. Ai3-26173
29. Diammonium 2-hydroxy-1,2,3-propanetricarboxylate
30. Ammonium Citrate Dibasic Acs Granular
31. Diazanium;3-carboxy-3-hydroxypentanedioate
32. Db-047712
33. 1,2,3-propanetricarboxylic Acid, 2-hydroxy-, Ammonium Salt (1:2)
| Molecular Weight | 226.18 g/mol |
|---|---|
| Molecular Formula | C6H14N2O7 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 3 |
| Exact Mass | 226.08010079 g/mol |
| Monoisotopic Mass | 226.08010079 g/mol |
| Topological Polar Surface Area | 140 Ų |
| Heavy Atom Count | 15 |
| Formal Charge | 0 |
| Complexity | 216 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
...The distribution of (15)N from ammonium citrate, administered by different routes, into the proteins of various tissues of hypophysectomized rats /was examined/. The liver, kidney, and spleen contained greater concentrations of (15)N incorporated into proteins than heart or muscle fractions during 72 hr following intragastric, intraperitoneal, and subcutaneous administration of 15N-ammonium citrate. After the first 6 hr, during which the intragastric route gave higher values, the quantity of (15)N incorporated into liver-protein was not substantially affected by the route of administration. In most of the other tissues studied, however, (15)N incorporation tended to be least by the intragastric route, followed, in increasing order, by the intraperitoneal and subcutaneous routes. By the last route, more labelled ammonia was apparently made available to the widely distributed glutamine-synthetase (EC 6.3.1.2) system. /Ammonium citrate/
WHO; Environ Health Criteria 54: Ammonia p.105 (1986)
Results of studies on the metabolic fate of dietary ammonium citrate and intravenously-administered ammonium lactate in rats showed that urea synthesis represented a nearly constant fraction of the administered ammonia over a large concentration range. Besides glutamine and urea, labelled nitrogen also appeared in creatine, glycine, alanine, proline, histidine, arginine, glutamic acid, and aspartic acid. ...The incorporation of (15)N from ammonium citrate into proteins of liver, heart, kidney, spleen, and muscle fractions of untreated and growth hormone-treated, hypophysectomized rats /was examined/, and found differences in the metabolic fate, depending on the route of administration. Subcutaneous injection facilitated the labelling of amide nitrogen, indicating extensive disposition via glutamine synthesis. In contrast, intragastric or intraperitoneal administration resulted in the labelling of arginine, glutamic acid, and other alpha-amino acids of the liver. Amide-nitrogen was labelled to a much lesser extent than by the subcutaneous route. The tissue distribution of the label also differed according to the route of entry. /Ammonium citrate/
WHO; Environ Health Criteria 54: Ammonia p.106 (1986)
ABOUT THIS PAGE
A Diammonium Citrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Diammonium Citrate, including repackagers and relabelers. The FDA regulates Diammonium Citrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Diammonium Citrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Diammonium Citrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Diammonium Citrate supplier is an individual or a company that provides Diammonium Citrate active pharmaceutical ingredient (API) or Diammonium Citrate finished formulations upon request. The Diammonium Citrate suppliers may include Diammonium Citrate API manufacturers, exporters, distributors and traders.
click here to find a list of Diammonium Citrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Diammonium Citrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Diammonium Citrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Diammonium Citrate GMP manufacturer or Diammonium Citrate GMP API supplier for your needs.
A Diammonium Citrate CoA (Certificate of Analysis) is a formal document that attests to Diammonium Citrate's compliance with Diammonium Citrate specifications and serves as a tool for batch-level quality control.
Diammonium Citrate CoA mostly includes findings from lab analyses of a specific batch. For each Diammonium Citrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Diammonium Citrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Diammonium Citrate EP), Diammonium Citrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Diammonium Citrate USP).
LOOKING FOR A SUPPLIER?
